Last week, Pfizer Inc. exercised the option it established earlier this year to acquire NextWave Pharmaceuticals for $255 million up front and potentially another $425 million based on certain sales milestones. Read More
Intellectual property (IP) is a cornerstone of the drug discovery industry. But as that industry is changing, some are questioning whether that cornerstone is starting to do more harm than good, at least the way it currently is constructed. Read More
